{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:57:09Z","timestamp":1792526229176,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,7,8]],"date-time":"2015-07-08T00:00:00Z","timestamp":1436313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2015,7,8]],"date-time":"2015-07-08T00:00:00Z","timestamp":1436313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000092","name":"U.S. National Library of Medicine","doi-asserted-by":"publisher","award":["R01: LM010016"],"award-info":[{"award-number":["R01: LM010016"]}],"id":[{"id":"10.13039\/100000092","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s40264-015-0314-8","type":"journal-article","created":{"date-parts":[[2015,7,7]],"date-time":"2015-07-07T17:41:00Z","timestamp":1436290860000},"page":"895-908","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["A Method to Combine Signals from Spontaneous Reporting Systems and Observational Healthcare Data to Detect Adverse Drug Reactions"],"prefix":"10.1007","volume":"38","author":[{"given":"Ying","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick B.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,8]]},"reference":[{"issue":"1","key":"314_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/jama.1995.03530010043033","volume":"274","author":"DW Bates","year":"1995","unstructured":"Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, et al. Incidence of adverse drug events and potential adverse drug events. JAMA. 1995;274(1):29\u201334.","journal-title":"JAMA"},{"issue":"2","key":"314_CR2","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S1086-5802(16)31229-3","volume":"41","author":"FR Ernst","year":"2001","unstructured":"Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Washington, DC: 1996). 2001;41(2):192.","journal-title":"J Am Pharm Assoc (Washington, DC: 1996)"},{"issue":"5","key":"314_CR3","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/00006254-199705000-00016","volume":"52","author":"DC Classen","year":"1997","unstructured":"Classen DC, Pestonik SL, Scott Evans R, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. Obstet Gynecol Surv. 1997;52(5):291.","journal-title":"Obstet Gynecol Surv"},{"issue":"8","key":"314_CR4","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.2105\/AJPH.2007.124537","volume":"98","author":"JA Berlin","year":"2008","unstructured":"Berlin JA, Glasser SC, Ellenberg SS. Adverse event detection in drug development: recommendations and obligations beyond phase 3. Am J Public Health. 2008;98(8):1366\u201371.","journal-title":"Am J Public Health"},{"issue":"1","key":"314_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1046\/j.1525-1497.2003.20130.x","volume":"18","author":"SR Ahmad","year":"2003","unstructured":"Ahmad SR. Adverse drug event monitoring at the Food and Drug Administration. J Gen Intern Med. 2003;18(1):57\u201360.","journal-title":"J Gen Intern Med"},{"issue":"1","key":"314_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00002018-199819010-00001","volume":"19","author":"S Olsson","year":"1998","unstructured":"Olsson S. The role of the WHO programme on international drug monitoring in coordinating worldwide drug safety efforts. Drug Saf. 1998;19(1):1\u201310.","journal-title":"Drug Saf"},{"issue":"6","key":"314_CR7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans S. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427\u201336.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"314_CR8","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/clpt.2012.50","volume":"91","author":"R Harpaz","year":"2012","unstructured":"Harpaz R, DuMouchel W, Shah N, Madigan D, Ryan P, Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther. 2012;91(6):1010\u201321.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"314_CR9","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1093\/clinids\/18.6.946","volume":"18","author":"MD Blum","year":"1994","unstructured":"Blum MD, Graham DJ, McCloskey CA. Temafloxacin syndrome: review of 95 cases. Clin Infect Dis. 1994;18(6):946\u201350.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"314_CR10","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s002280050498","volume":"54","author":"A Alvarez-Requejo","year":"1998","unstructured":"Alvarez-Requejo A, Carvajal A, Begaud B, Moride Y, Vega T, Arias LM. Under-reporting of adverse drug reactions estimate based on a spontaneous reporting scheme and a sentinel system. Eur J Clin Pharmacol. 1998;54(6):483\u20138.","journal-title":"Eur J Clin Pharmacol"},{"issue":"25","key":"314_CR11","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1056\/NEJM199506223322502","volume":"332","author":"J Sanchez-Guerrero","year":"1995","unstructured":"Sanchez-Guerrero J, Colditz GA, Karlson EW, Hunter DJ, Speizer FE, Liang MH. Silicone breast implants and the risk of connective-tissue diseases and symptoms. N Engl J Med. 1995;332(25):1666\u201370.","journal-title":"N Engl J Med"},{"issue":"3","key":"314_CR12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jadohealth.2013.09.005","volume":"54","author":"JM Eberth","year":"2014","unstructured":"Eberth JM, Kline KN, Moskowitz DA, Montealegre JR, Scheurer ME. The role of media and the internet on vaccine adverse event reporting: a case study of human papillomavirus vaccination. J Adolesc Health. 2014;54(3):289\u201395.","journal-title":"J Adolesc Health"},{"issue":"1","key":"314_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pds.2053","volume":"20","author":"PM Coloma","year":"2011","unstructured":"Coloma PM, Schuemie MJ, Trifir\u00f2 G, Gini R, Herings R, Hippisley-Cox J, et al. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR project. Pharmacoepidemiol Drug Saf. 2011;20(1):1\u201311.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"314_CR14","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1197\/jamia.M3028","volume":"16","author":"X Wang","year":"2009","unstructured":"Wang X, Hripcsak G, Markatou M, Friedman C. Active computerized pharmacovigilance using natural language processing, statistics, and electronic health records: a feasibility study. J Am Med Inform Assoc. 2009;16(3):328\u201337.","journal-title":"J Am Med Inform Assoc"},{"issue":"6","key":"314_CR15","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/clpt.2013.47","volume":"93","author":"P LePendu","year":"2013","unstructured":"LePendu P, Iyer SV, Bauer-Mehren A, Harpaz R, Mortensen JM, Podchiyska T, et al. Pharmacovigilance using clinical notes. Clin Pharmacol Ther. 2013;93(6):547\u201355","journal-title":"Clin Pharmacol Ther."},{"issue":"9","key":"314_CR16","doi-asserted-by":"publisher","first-page":"600","DOI":"10.7326\/0003-4819-153-9-201011020-00010","volume":"153","author":"PE Stang","year":"2010","unstructured":"Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med. 2010;153(9):600.","journal-title":"Ann Intern Med"},{"issue":"1","key":"314_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11096-014-0044-5","volume":"37","author":"VK Patadia","year":"2015","unstructured":"Patadia VK, Schuemie MJ, Coloma P, Herings R, van der Lei J, Straus S, et al. Evaluating performance of electronic healthcare records and spontaneous reporting data in drug safety signal detection. Int J Clin Pharm. 2015;37(1):94\u2013104","journal-title":"Int J Clin Pharm."},{"issue":"7","key":"314_CR18","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMp0905338","volume":"361","author":"R Platt","year":"2009","unstructured":"Platt R, Wilson M, Chan KA, Benner JS, Marchibroda J, McClellan M. The new Sentinel Network\u2014improving the evidence of medical-product safety. N Engl J Med. 2009;361(7):645\u20137.","journal-title":"N Engl J Med"},{"issue":"1","key":"314_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s40264-013-0108-9","volume":"36","author":"PB Ryan","year":"2013","unstructured":"Ryan PB, Stang PE, Overhage JM, Suchard MA, Hartzema AG, DuMouchel W, et al. A comparison of the empirical performance of methods for a risk identification system. Drug Saf. 2013;36(1):143\u201358.","journal-title":"Drug Saf"},{"issue":"30","key":"314_CR20","doi-asserted-by":"publisher","first-page":"4401","DOI":"10.1002\/sim.5620","volume":"31","author":"PB Ryan","year":"2012","unstructured":"Ryan PB, Madigan D, Stang PE, Marc Overhage J, Racoosin JA, Hartzema AG. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012;31(30):4401\u201315","journal-title":"Stat Med."},{"issue":"10","key":"314_CR21","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1097\/MLR.0b013e31825f63bf","volume":"50","author":"MJ Schuemie","year":"2012","unstructured":"Schuemie MJ, Coloma PM, Straatman H, Herings RM, Trifir\u00f2 G, Matthews JN, et al. Using electronic health care records for drug safety signal detection: a comparative evaluation of statistical methods. Med Care. 2012;50(10):890\u20137.","journal-title":"Med Care"},{"issue":"1","key":"314_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/clpt.2011.83","volume":"90","author":"N Tatonetti","year":"2011","unstructured":"Tatonetti N, Denny J, Murphy S, Fernald G, Krishnan G, Castro V, et al. Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels. Clin Pharmacol Ther. 2011;90(1):133\u201342.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"314_CR23","doi-asserted-by":"publisher","first-page":"e1002614","DOI":"10.1371\/journal.pcbi.1002614","volume":"8","author":"JD Duke","year":"2012","unstructured":"Duke JD, Han X, Wang Z, Subhadarshini A, Karnik SD, Li X, et al. Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions. PLoS Comput Biol. 2012;8(8):e1002614.","journal-title":"PLoS Comput Biol"},{"issue":"9","key":"314_CR24","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1038\/psp.2014.35","volume":"3","author":"S Vilar","year":"2014","unstructured":"Vilar S, Ryan P, Madigan D, Stang P, Schuemie M, Friedman C, et al. Similarity-based modeling applied to signal detection in pharmacovigilance. CPT Pharmacometrics Syst Pharmacol. 2014;3(9):e137.","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"key":"314_CR25","doi-asserted-by":"crossref","unstructured":"Harpaz R, DuMouchel W, LePendu P, Shah NH. Empirical bayes model to combine signals of adverse drug reactions. In: Proceedings of the 19th ACM SIGKDD international conference on Knowledge discovery and data mining. ACM; 2013. p. 1339\u201347.","DOI":"10.1145\/2487575.2488214"},{"issue":"1","key":"314_CR26","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/amiajnl-2014-002649","volume":"22","author":"H Xu","year":"2015","unstructured":"Xu H, Aldrich MC, Chen Q, Liu H, Peterson NB, Dai Q, et al. Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality. J Am Med Inform Assoc. 2015;22(1):179\u201391","journal-title":"J Am Med Inform Assoc."},{"issue":"9","key":"314_CR27","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/bioinformatics\/btq126","volume":"26","author":"JC Denny","year":"2010","unstructured":"Denny JC, Ritchie MD, Basford MA, Pulley JM, Bastarache L, Brown-Gentry K, et al. PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene\u2013disease associations. Bioinformatics. 2010;26(9):1205\u201310.","journal-title":"Bioinformatics"},{"issue":"Suppl 1","key":"314_CR28","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/2041-1480-3-S1-S5","volume":"3","author":"P LePendu","year":"2012","unstructured":"LePendu P, Iyer SV, Fairon C, Shah NH. Annotation analysis for testing drug safety signals using unstructured clinical notes. J Biomed Semantics. 2012;3(Suppl 1):S5.","journal-title":"J Biomed Semantics."},{"issue":"3","key":"314_CR29","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1136\/amiajnl-2012-000930","volume":"20","author":"R Harpaz","year":"2013","unstructured":"Harpaz R, Vilar S, DuMouchel W, Salmasian H, Haerian K, Shah NH, et al. Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions. J Am Med Inform Assoc. 2013;20(3):413\u20139","journal-title":"J Am Med Inform Assoc."},{"issue":"2","key":"314_CR30","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/clpt.2012.54","volume":"92","author":"K Haerian","year":"2012","unstructured":"Haerian K, Varn D, Vaidya S, Ena L, Chase H, Friedman C. Detection of pharmacovigilance-related adverse events using electronic health records and automated methods. Clin Pharmacol Ther. 2012;92(2):228\u201334.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"314_CR31","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1136\/amiajnl-2013-001718","volume":"21","author":"Y Li","year":"2014","unstructured":"Li Y, Salmasian H, Vilar S, Chase H, Friedman C, Wei Y. A method for controlling complex confounding effects in the detection of adverse drug reactions using electronic health records. J Am Med Inform Assoc. 2014;21(2):308\u201314","journal-title":"J Am Med Inform Assoc."},{"issue":"1","key":"314_CR32","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/amiajnl-2011-000214","volume":"19","author":"NP Tatonetti","year":"2012","unstructured":"Tatonetti NP, Fernald GH, Altman RB. A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J Am Med Inform Assoc. 2012;19(1):79\u201385.","journal-title":"J Am Med Inform Assoc"},{"issue":"4","key":"314_CR33","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/sam.10078","volume":"3","author":"O Caster","year":"2010","unstructured":"Caster O, Nor\u00e9n GN, Madigan D, Bate A. Large-scale regression-based pattern discovery: the example of screening the WHO global drug safety database. Stat Anal Data Min. 2010;3(4):197\u2013208.","journal-title":"Stat Anal Data Min."},{"issue":"6","key":"314_CR34","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/clpt.2013.24","volume":"93","author":"R Harpaz","year":"2013","unstructured":"Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther. 2013;93(6):539\u201346","journal-title":"Clin Pharmacol Ther."},{"issue":"12","key":"314_CR35","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1002\/pds.1836","volume":"18","author":"G Trifir\u00f2","year":"2009","unstructured":"Trifir\u00f2 G, Pariente A, Coloma PM, Kors JA, Polimeni G, Miremont-Salam\u00e9 G, et al. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? Pharmacoepidemiol Drug Saf. 2009;18(12):1176\u201384.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"314_CR36","unstructured":"FDA Adverse Event Reporting System (FAERS). [cited]; Available from: http:\/\/www.fda.gov\/cder\/aers\/default.htm ."},{"issue":"suppl 1","key":"314_CR37","first-page":"D684","volume":"36","author":"M Kuhn","year":"2008","unstructured":"Kuhn M, von Mering C, Campillos M, Jensen LJ, Bork P. STITCH: interaction networks of chemicals and proteins. Nucleic Acids Res. 2008;36(suppl 1):D684\u20138.","journal-title":"Nucleic Acids Res"},{"key":"314_CR38","unstructured":"Medical Dictionary for Regulatory Activities (MedDRA\u00ae). [cited]; Available from: http:\/\/www.meddramsso.com ."},{"issue":"1","key":"314_CR39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40264-013-0097-8","volume":"36","author":"PB Ryan","year":"2013","unstructured":"Ryan PB, Schuemie MJ, Welebob E, Duke J, Valentine S, Hartzema AG. Defining a reference set to support methodological research in drug safety. Drug Saf. 2013;36(1):33\u201347.","journal-title":"Drug Saf"},{"issue":"1","key":"314_CR40","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40264-013-0111-1","volume":"36","author":"CG Reich","year":"2013","unstructured":"Reich CG, Ryan PB, Schuemie MJ. Alternative outcome definitions and their effect on the performance of methods for observational outcome studies. Drug Saf. 2013;36(1):181\u201393.","journal-title":"Drug Saf"},{"key":"314_CR41","doi-asserted-by":"crossref","unstructured":"Belloni A, Chernozhukov V, Wei Y. Honest confidence regions for a regression parameter in logistic regression with a large number of controls. 2013 (arXiv preprint arXiv:13043969).","DOI":"10.1920\/wp.cem.2013.6713"},{"issue":"3","key":"314_CR42","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1148\/radiology.148.3.6878708","volume":"148","author":"JA Hanley","year":"1983","unstructured":"Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148(3):839\u201343.","journal-title":"Radiology"},{"issue":"1","key":"314_CR43","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinform. 2011;12(1):77.","journal-title":"BMC Bioinform"},{"issue":"1","key":"314_CR44","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/clpt.2011.369","volume":"92","author":"JJ Gagne","year":"2012","unstructured":"Gagne JJ, Glynn RJ, Rassen JA, Walker AM, Daniel GW, Sridhar G, et al. Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system. Clin Pharmacol Ther. 2012;92(1):80\u20136.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"314_CR45","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/EDE.0b013e3181a663cc","volume":"20","author":"S Schneeweiss","year":"2009","unstructured":"Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology (Cambridge, Mass). 2009;20(4):512.","journal-title":"Epidemiology (Cambridge, Mass)"},{"issue":"30","key":"314_CR46","doi-asserted-by":"publisher","first-page":"4401","DOI":"10.1002\/sim.5620","volume":"31","author":"PB Ryan","year":"2012","unstructured":"Ryan PB, Madigan D, Stang PE, Marc Overhage J, Racoosin JA, Hartzema AG. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012;31(30):4401\u201315.","journal-title":"Stat Med"},{"issue":"9","key":"314_CR47","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s40264-014-0198-z","volume":"37","author":"GN Nor\u00e9n","year":"2014","unstructured":"Nor\u00e9n GN, Caster O, Juhlin K, Lindquist M. Zoo or savannah? Choice of training ground for evidence-based pharmacovigilance. Drug Saf. 2014;37(9):655\u20139.","journal-title":"Drug Saf"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-015-0314-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-015-0314-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-015-0314-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-015-0314-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T19:47:07Z","timestamp":1652816827000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-015-0314-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,8]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["314"],"URL":"https:\/\/doi.org\/10.1007\/s40264-015-0314-8","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,8]]},"assertion":[{"value":"8 July 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work is supported by the National Library of Medicine Grants R01: LM010016.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='BoldItalic' removed-->Funding"}},{"value":"Patrick B. Ryan is an employee of Janssen Research and Development, and a shareholder of Johnson & Johnson. Carol Friedman is a consultant for Health Fidelity. Ying Li and Ying Wei have no conflicts of interest that are directly relevant to the content of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='BoldItalic' removed-->Conflicts of interest"}},{"value":"The Institutional Review Board of Columbia University approved the study based on Columbia University Medical Center\/New York Presbyterian Hospital (CUMC\/NYP) data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='BoldItalic' removed-->Ethical approval"}}]}}